This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sammaritano, L. R. Articles by Gharavi, A. E. Search for Related Content PubMed PubMed Citation Articles by Sammaritano, L. R. Articles by Gharavi, A. E. Social Bookmarking                         What's this?

Antiphospholipid Antibodies Differ in aPL Cofactor Requirement

Hospital for Special Surgery, Cornell University Medical Center, 535 East 70th Street, New York, NY 10021, USA

Michael D. Lockshin

Hospital for Special Surgery, Cornell University Medical Center, 535 East 70th Street, New York, NY 10021, USA

Azzudin E. Gharavi

Hospital for Special Surgery, Cornell University Medical Center, 535 East 70th Street, New York, NY 10021, USA

Although autoimmune antiphospholipid antibodies (aPL) may require a serum cofactor, beta₂-glycoprotein I (ß₂GPI), for maximal binding in aPL ELISA, it is not known whether cofactor is absolutely required or is merely an enhancing factor for binding, nor is it clear whether aPL bind to cofactor itself, a cofactor-lipid complex, or a phospholipid modified in some way by cofactor. We therefore isolated and purified ß₂GPI and evaluated its relationship to both IgG and IgM aPL binding. aPL derived from different sera appear to have differing requirements for cofactor; the proportion of total binding attributable to cofactor varies from 46% to 95%. aPL do not bind to ß ₂GPI in the absence of phospholipid. Enhanced binding to phospholipid is seen if ß₂GPI is provided either before or with the test antibody. Autoimmune aPL bind phospholipid better with human rather than bovine cofactor. The requirement for cofactor is greater for low-avidity aPL as measured in an IgG-human cofactor system. Cofactor requirement alone does not predict the presence or absence of associated clinical complications.

Key Words: Antiphospholipid antibody • Lupus cofactor • aPL cofactor • ß2-glycoprotein I • Apolipoprotein H

Lupus, Vol. 1, No. 2, 83-90 (1992)
DOI: 10.1177/096120339200100205


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P Soltesz, K Veres, G Lakos, E Kiss, L Muszbek, and G Szegedi Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients Lupus, April 1, 2003; 12(4): 302 - 307. [Abstract] [PDF]

				Y S Haviv Association of anticardiolipin antibodies with vascular injury: possible mechanisms Postgrad. Med. J., October 1, 2000; 76(900): 625 - 628. [Full Text]

				Y Shoenfeld, A Gharavi, and T Koike b2GP-I in the anti phospholipid (Hughes') syndrome--from a cofactor to an autoantigen -- from induction to prevention of antiphospholipid syndrome Lupus, October 1, 1998; 7(8): 503 - 506. [PDF]

				Y. Sheng, D. A. Kandiah, and S. A. Krilis Anti-{beta}2-Glycoprotein I Autoantibodies from Patients with the "Antiphospholipid" Syndrome Bind to {beta}2-Glycoprotein I with Low Affinity: Dimerization of {beta}2-Glycoprotein I Induces a Significant Increase in Anti-{beta}2-Glycoprotein I Antibody Affinity J. Immunol., August 15, 1998; 161(4): 2038 - 2043. [Abstract] [Full Text] [PDF]

				M. Hojnik, J. George, L. Ziporen, and Y. Shoenfeld Heart Valve Involvement (Libman-Sacks Endocarditis) in the Antiphospholipid Syndrome Circulation, April 15, 1996; 93(8): 1579 - 1587. [Abstract] [Full Text]

				M. Hojnik, B. Gilburd, L. Ziporen, M. Blank, Y. Tomer, M. A. Scheinberg, A. Tincani, B. Rozman, and Y. Shoenfeld Anticardiolipin Antibodies in Infections are Heterogenous in Their Dependency on {beta} 2-Glycoprotein I: Analysis of Anticardiolipin Antibodies in Leprosy Lupus, December 1, 1994; 3(6): 515 - 521. [Abstract] [PDF]

				D. A. Kandiah and S. A. Krilis Beta2-Glycoprotein I Lupus, August 1, 1994; 3(4): 207 - 212. [PDF]

				D. Kandiah, J. Hunt, and S. Krilis Epitope mapping studies of antiphospholipid antibodies and {beta}2-GPI using synthetic peptides Lupus, July 1, 1994; 4(1_suppl): S7 - S11. [PDF]

				J. E. Hunt and S. A. Krilis Antiphosphotipid Antibodies, {beta}2-Glycoprotein I and Thrombosis Lupus, October 1, 1993; 2(5): 285 - 287. [PDF]

				E. Rossi and M. Costa Fish Oil Derivatives as a Prophylaxis of Recurrent Miscarriage Associated with Antiphospholipid Antibodies (APL) : a Pilot Study Lupus, October 1, 1993; 2(5): 319 - 323. [Abstract] [PDF]